The FDA has approved Pfizer’s review request for marstacimab, a hemophilia A/B treatment for non-inhibitor patients.

SystImmune and industry giant Bristol Myers Squibb have announced a partnership and licensing agreement focused on BL-B01D1, SystImmune's cutting-edge EGFRxHER3 bispecific antibody-drug conjugate.

Oculis Reveals Initial Participant Commencement in Phase 2b RELIEF Study for Topical Anti-TNFα Agent Licaminlimab (OCS-02) Aimed at Treating Dry Eye Conditions.

Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data.

AltruBio Inc. starts Phase 2a trial for its drug ALTB-268 in ulcerative colitis patients with the first participant enrolled.

Vittoria Biotherapeutics Reveals US FDA Approval of Investigational New Drug Submission for VIPER-101 to Address T-Cell Lymphoma Therapy.

Bio-Thera Solutions, Ltd has made public the approval of their product Avzivi® (bevacizumab-tnjn) by the United States Food and Drug Administration.

ExeGi Pharma, a biopharmaceutical pioneer in live biotherapeutics, has commenced patient enrollment for its pivotal PROF Trial to test EXE-346, a new treatment targeting frequent bowel movements post ileal pouch-anal anastomosis surgery.

Pfizer Inc. has released an announcement that the European Commission has provided a conditional marketing approval for their product, ELREXFIO (elranatamab).

Vertex and CRISPR Therapeutics have declared that CASGEVY™ has been officially sanctioned by the FDA to combat sickle cell disease.

DAN-222 from Dantari has exhibited encouraging results in shrinking tumors for those suffering from advanced breast cancer that lacks the HER2 protein.

Ractigen Therapeutics, a pioneer in saRNA therapy, has submitted an Australian clinical trial application to commence a Phase I trial.